{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:15:33Z","timestamp":1792782933078,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-004"],"award-info":[{"award-number":["2022-PUMCH-C-004"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["3332022110"],"award-info":[{"award-number":["3332022110"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2021-I2M-1-016"],"award-info":[{"award-number":["2021-I2M-1-016"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-A-008"],"award-info":[{"award-number":["2022-I2M-C&T-A-008"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272046"],"award-info":[{"award-number":["82272046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22176016"],"award-info":[{"award-number":["22176016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00259-024-06721-x","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T23:37:06Z","timestamp":1714001826000},"page":"2794-2805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study"],"prefix":"10.1007","volume":"51","author":[{"given":"Linlin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alexoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Ploessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-8049","authenticated-orcid":false,"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"6721_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"Ca Cancer J Clin"},{"key":"6721_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.123.265670","volume":"64","author":"WA Weber","year":"2023","unstructured":"Weber WA, Barthel H, Bengel F, Eiber M, Herrmann K, Sch\u00e4fers M, What. Is Theranostics? J Nucl Med. 2023;64:669\u201370. https:\/\/doi.org\/10.2967\/jnumed.123.265670.","journal-title":"Is Theranostics? J Nucl Med"},{"key":"6721_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:1\u201312.","journal-title":"Ther Adv Med Oncol"},{"key":"6721_CR4","doi-asserted-by":"publisher","unstructured":"Sartor O, Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","DOI":"10.1056\/NEJMoa2107322"},{"key":"6721_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-Approved Radiotherapeutical for treatment of prostate Cancer. Pharmaceuticals. 2022;15:1292.","journal-title":"Pharmaceuticals"},{"key":"6721_CR6","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023:1\u201316.","DOI":"10.1007\/s00259-023-06255-8"},{"key":"6721_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358. https:\/\/doi.org\/10.1007\/s00259-018-4096-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6721_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","volume":"51","author":"J Zang","year":"2023","unstructured":"Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023;51:871\u201382. https:\/\/doi.org\/10.1007\/s00259-023-06470-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6721_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","volume":"48","author":"V Kramer","year":"2021","unstructured":"Kramer V, Fern\u00e1ndez R, Lehnert W, Jim\u00e9nez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893\u2013903. https:\/\/doi.org\/10.1007\/s00259-020-05022-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6721_CR10","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1021\/cr500171e","volume":"115","author":"S Banerjee","year":"2015","unstructured":"Banerjee S, Pillai MR, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115:2934\u201374. https:\/\/doi.org\/10.1021\/cr500171e.","journal-title":"Chem Rev"},{"key":"6721_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.semnuclmed.2023.06.007","volume":"0","author":"S Alati","year":"2023","unstructured":"Alati S, Singh R, Pomper MG, Rowe SP, Banerjee SR. Preclinical Development in Radiopharmaceutical Therapy for prostate Cancer. Semin Nucl Med. 2023;0:1\u201312. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.06.007.","journal-title":"Semin Nucl Med"},{"key":"6721_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/ijms23031158","volume":"23","author":"S Debnath","year":"2022","unstructured":"Debnath S, Zhou N, McLaughlin M, Rice S, Pillai AK, Hao G, et al. PSMA-Targeting Imaging and Theranostic agents-current status and future perspective. Int J Mol Sci. 2022;23:1158\u201377. https:\/\/doi.org\/10.3390\/ijms23031158.","journal-title":"Int J Mol Sci"},{"key":"6721_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","volume":"52","author":"P Jackson","year":"2022","unstructured":"Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in 177Lu-PSMA-617 therapy. Semin Nucl Med. 2022;52:243\u201354. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.003.","journal-title":"Semin Nucl Med"},{"key":"6721_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K. MIRD Pamphlet 26: Joint EANM\/MIRD guidelines for quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med. 2016;57:151\u201362. https:\/\/doi.org\/10.2967\/jnumed.115.159012.","journal-title":"J Nucl Med"},{"key":"6721_CR15","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1088\/0031-9155\/41\/10\/001","volume":"41","author":"RG Dale","year":"1996","unstructured":"Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871\u201384. https:\/\/doi.org\/10.1088\/0031-9155\/41\/10\/001.","journal-title":"Phys Med Biol"},{"key":"6721_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/clon.2001.9221","volume":"13","author":"B Jones","year":"2001","unstructured":"Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DAL. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol. 2001;13:71\u201381. https:\/\/doi.org\/10.1053\/clon.2001.9221.","journal-title":"Clin Oncol"},{"key":"6721_CR17","doi-asserted-by":"publisher","first-page":"13001","DOI":"10.1021\/acs.jmedchem.2c00852","volume":"65","author":"Z Zha","year":"2022","unstructured":"Zha Z, Choi SR, Li L, Zhao R, Ploessl K, Yao X, et al. New PSMA-Targeting ligands: Transformation from diagnosis (Ga-68) to Radionuclide Therapy (Lu-177). J Med Chem. 2022;65:13001\u201312. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00852.","journal-title":"J Med Chem"},{"key":"6721_CR18","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.tranon.2022.101450","volume":"22","author":"TM Jeitner","year":"2022","unstructured":"Jeitner TM, Babich JW, Kelly JM. Advances in PSMA theranostics. Transl Oncol. 2022;22:101450. https:\/\/doi.org\/10.1016\/j.tranon.2022.101450.","journal-title":"Transl Oncol"},{"key":"6721_CR19","doi-asserted-by":"publisher","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49. https:\/\/doi.org\/10.1007\/s00259-022-05727-7.","DOI":"10.1007\/s00259-022-05727-7"},{"key":"6721_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","volume":"5","author":"L Evangelista","year":"2022","unstructured":"Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, et al. [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography\/Computed Tomography in the staging of primary and recurrent prostate Cancer. A systematic review of the literature. Eur Urol Oncol. 2022;5:273\u201382. https:\/\/doi.org\/10.1016\/j.euo.2022.03.004.","journal-title":"Eur Urol Oncol"},{"key":"6721_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"6721_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MNM.0000000000000662","volume":"38","author":"ET Hippel\u00e4inen","year":"2017","unstructured":"Hippel\u00e4inen ET, Tenhunen MJ, M\u00e4enp\u00e4\u00e4 HO, Heikkonen JJ, Sohlberg AO. Dosimetry software Hermes Internal Radiation Dosimetry: from quantitative image reconstruction to voxel-level absorbed dose distribution. Nucl Med Commun. 2017;38:357\u201365. https:\/\/doi.org\/10.1097\/MNM.0000000000000662.","journal-title":"Nucl Med Commun"},{"key":"6721_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, M\u00fcller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63:1199\u2013207.","journal-title":"J Nucl Med"},{"key":"6721_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2967\/jnumed.121.262671","volume":"63","author":"B Feuerecker","year":"2022","unstructured":"Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L. Pretherapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63:833\u20139. https:\/\/doi.org\/10.2967\/jnumed.121.262671.","journal-title":"J Nucl Med"},{"key":"6721_CR25","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.120.242263","volume":"61","author":"J Zang","year":"2020","unstructured":"Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, et al. 177Lu-EB-PSMA Radioligand Therapy with escalating doses in patients with metastatic castration-resistant prostate Cancer. J Nucl Med. 2020;61:1772\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.242263.","journal-title":"J Nucl Med"},{"key":"6721_CR26","doi-asserted-by":"publisher","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"6721_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/s1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/s1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"6721_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","volume":"59","author":"Z Zha","year":"2018","unstructured":"Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF. Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor. Nucl Med Biol. 2018;59:36\u201347. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.007.","journal-title":"Nucl Med Biol"},{"key":"6721_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11307-019-01421-7","volume":"22","author":"MA Green","year":"2020","unstructured":"Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, et al. [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for detection of Cancer: initial evaluation and comparison with [68Ga]Ga-PSMA-11 in prostate Cancer patients presenting with biochemical recurrence. Mol Imaging Biol. 2020;22:752\u201363. https:\/\/doi.org\/10.1007\/s11307-019-01421-7.","journal-title":"Mol Imaging Biol"},{"key":"6721_CR30","first-page":"1","volume":"26","author":"H Lee","year":"2022","unstructured":"Lee H, Scheuermann JS, Young AJ, Doot RK, Daube-Witherspoon ME, Schubert EK, et al. Preliminary evaluation of 68Ga-P16-093, a PET Radiotracer Targeting prostate-specific membrane Antigen in prostate Cancer. Mol Imaging Biol. 2022;26:1\u201311.","journal-title":"Mol Imaging Biol"},{"key":"6721_CR31","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","volume":"49","author":"G Wang","year":"2022","unstructured":"Wang G, Hong H, Zang J, Liu Q, Jiang Y, Fan X, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2022;49:1052\u201362. https:\/\/doi.org\/10.1007\/s00259-021-05539-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6721_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1021\/bc050282y","volume":"17","author":"CE Dumelin","year":"2006","unstructured":"Dumelin CE, Scheuermann J, Melkko S, Neri D. Selection of streptavidin binders from a DNA-encoded chemical library. Bioconjug Chem. 2006;17:366\u201370.","journal-title":"Bioconjug Chem"},{"key":"6721_CR33","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1002\/anie.200704936","volume":"47","author":"CE Dumelin","year":"2008","unstructured":"Dumelin CE, Tr\u00fcssel S, Buller F, Trachsel E, Bootz F, Zhang Y, et al. A portable albumin Binder from a DNA-Encoded Chemical Library. Angew Chem Int Ed. 2008;47:3196\u2013201. https:\/\/doi.org\/10.1002\/anie.200704936.","journal-title":"Angew Chem Int Ed"},{"key":"6721_CR34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2967\/jnumed.118.221150","volume":"60","author":"JM Kelly","year":"2019","unstructured":"Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr., DiMagno SG, et al. Albumin-binding PSMA ligands: implications for expanding the therapeutic window. J Nucl Med. 2019;60:656\u201363. https:\/\/doi.org\/10.2967\/jnumed.118.221150.","journal-title":"J Nucl Med"},{"key":"6721_CR35","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Benesova M, Schibli R, Muller C, Kelly J, Amor-Coarasa A, et al. Preclinical Development of Novel PSMA-Targeting Radioligands: modulation of albumin-binding. Mol Pharm. 2018;15:2297\u2013306. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00152.","journal-title":"Mol Pharm"},{"key":"6721_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-021-00543-8","volume":"18","author":"P Sidaway","year":"2021","unstructured":"Sidaway P. 177Lu-PSMA-PET extends survival. Nat Rev Clin Oncol. 2021;18:510. https:\/\/doi.org\/10.1038\/s41571-021-00543-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"6721_CR37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","volume":"15","author":"M Benesova","year":"2018","unstructured":"Benesova M, Umbricht CA, Schibli R, Muller C, Albumin-Binding PSMA, Ligands. Optimization of the tissue distribution Profile. Mol Pharm. 2018;15:934\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00877.","journal-title":"Mol Pharm"},{"key":"6721_CR38","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","volume":"15","author":"HT Kuo","year":"2018","unstructured":"Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, et al. Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: Preclinical Dosimetry and Endoradiotherapy studies. Mol Pharm. 2018;15:5183\u201391. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00720.","journal-title":"Mol Pharm"},{"key":"6721_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2967\/jnumed.120.250738","volume":"62","author":"HT Kuo","year":"2021","unstructured":"Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, et al. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting agents with extremely high Tumor Uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med. 2021;62:521\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.250738.","journal-title":"J Nucl Med"},{"key":"6721_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3348\/kjr.2023.0656","volume":"25","author":"S Ha","year":"2024","unstructured":"Ha S, Park C, Boo SH, Yoo IR, Moon HW, Chi DY, et al. Dosimetric Analysis of a phase I study of PSMA-Targeting Radiopharmaceutical Therapy with [177Lu]ludotadipep in patients with metastatic castration-resistant prostate Cancer. Korean J Radiol. 2024;25:179\u201388.","journal-title":"Korean J Radiol"},{"key":"6721_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","volume":"48","author":"V Kramer","year":"2021","unstructured":"Kramer V, Fern\u00e1ndez R, Lehnert W, Jim\u00e9nez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893\u2013903.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6721_CR42","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1021\/acs.molpharmaceut.0c00199","volume":"17","author":"F Borgna","year":"2020","unstructured":"Borgna F, Deberle LM, Cohrs S, Schibli R, M\u00fcller C. Combined application of albumin-binding [177Lu]Lu-PSMA-ALB-56 and fast-cleared psma inhibitors: optimization of the Pharmacokinetics. Mol Pharm. 2020;17:2044\u201353.","journal-title":"Mol Pharm"},{"key":"6721_CR43","doi-asserted-by":"publisher","unstructured":"Derlin T, Riethdorf S, Schumacher U, Lafos M, Peine S, Coith C, et al. PSMA-heterogeneity in metastatic castration\u2010resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;1\u201313. https:\/\/doi.org\/10.1002\/pros.24549.","DOI":"10.1002\/pros.24549"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06721-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:03:57Z","timestamp":1720091037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06721-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6721"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06721-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institute Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (no. ZS-3567), and registered at clinicaltrials.gov (NCT05603559).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"David Alexoff, Karl Ploessl and Hank F. Kung are employees of Five Eleven Pharma Inc. which holds the patent rights for [<sup>177<\/sup>Lu]Lu-P17-087 and [<sup>177<\/sup>Lu]Lu-P17-088 and related technology. Dr. Hank F. Kung is also the Founder and Chairman of the board at Five Eleven Pharma Inc. Other authors declare no other conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}